A brain-computer interface company that wants to sell an implantable device in China now has a definitive answer to a question that had been open all year: what medical device class does the National Medical Products Administration (NMPA) put it in. The answer is Class III, the highest tier, non-negotiable. Non-invasive BCIs are also Class III by default, with one narrow exception. That exception is non-invasive devices for stroke motor rehabilitation that do not incorporate artificial intelligence: those get Class II. Add an AI decoding layer to a stroke-rehab device and it reverts to Class III.

The NMPA published Announcement No. 24 (2026) on 29 June 2026 titled 《脑机接口医疗器械产品分类界定指导原则》, or “Guiding Principles for the Classification and Definition of Brain-Computer Interface Medical Device Products.” A companion document, 《脑机接口医疗器械通用名称命名指导原则》 (“Generic Naming Guidelines for Brain-Computer Interface Medical Device Products”), was published under the same announcement. The China Briefing publication run by Dezan Shira & Associates covered the announcement on 3 July 2026 in an analysis piece by Qian Zhou, which is what surfaced the story to Western trade press. This Inside BCI report combines the China Briefing analysis with verbatim primary-text verification from the NMPA-mirror sources at LexisCN, Sina Finance, and IT之家, cross-referenced against the March 2026 draft consultation record. Specialist Western regulatory trade coverage (RAPS Regulatory Focus, Emergo by UL, RegDesk, BioWorld MedTech, MedTech Dive) had not yet picked up the announcement at the time of publication.

The classification framework

The Guiding Principles specify five permutations across three variables: invasiveness (invasive or non-invasive), clinical purpose (disease treatment, functional compensation, or rehabilitation), and, for non-invasive rehabilitation devices, whether the device incorporates AI technology as defined in the NMPA’s existing AI Medical Device Registration Review Guideline.

The permutations map as follows. Invasive or implantable BCIs, whatever their clinical purpose, are classified Class III under subcategory code 12-00 (active implantable medical devices). Non-invasive BCIs for disease treatment are Class III under subcategory 09-00. Non-invasive BCIs for functional compensation or general rehabilitation are Class III under subcategory 19-00. Non-invasive BCIs specifically for stroke motor rehabilitation, in the absence of AI technology, are Class II under subcategory 19-00. Non-invasive BCIs for other rehabilitation categories are Class III. Every other permutation, in short, lands in Class III.

The AI trigger deserves specific attention. The Guiding Principles do not define AI narrowly to mean neural-signal decoding. The definition of “AI technology” is imported wholesale from the NMPA’s existing AI Medical Device Registration Review Guideline (《人工智能医疗器械注册审查指导原则》). This means that machine learning, deep learning, and any adaptive or self-learning algorithmic components fall under the AI umbrella for classification purposes, regardless of whether the AI is applied to decoding, signal processing, artefact removal, or user interface adaptation. The NMPA rationale disclosed in the interpretive commentary is that AI algorithms can misjudge patient intent and cause motion injury (误判患者意图导致运动损伤), which is why the AI presence upgrades stroke-rehab devices from Class II to the higher-risk Class III tier.

What counts as a BCI medical device, and what does not

The Guiding Principles include a specific verbatim definition of the regulated category. The definition, translated from the Chinese source text, is: an active medical device that, through invasive or non-invasive means, measures neural signals produced by the central nervous system and decodes them in real time, enables real-time two-way interaction or closed-loop feedback between the patient and external auxiliary or diagnostic-therapeutic equipment, and achieves clinical effects such as the improvement, restoration, or replacement of central nervous system function. The Chinese original uses the phrase 有源医疗器械 (active medical device), which is regulatory-specific and excludes passive devices from the category.

Four categories are explicitly excluded. First, devices that measure only peripheral nerve signals, electromyography, electrocardiography, or related peripheral-body signals rather than central nervous system signals. Second, devices that operate only one-way, either collecting neural signals without providing feedback (collect-only) or providing stimulation without responding to neural signal input (stimulate-only). Third, devices for non-medical purposes, including gaming, virtual reality, augmented reality, and general daily-life cognitive augmentation. Fourth, devices where the CNS measurement functions only as an auxiliary component of another regulated device rather than as the primary function.

Standalone electroencephalography (EEG) analysis software that operates on stored data without a real-time decode-and-feedback loop is pushed out of the previously ambiguous BCI-adjacent subcategory 21 by the same Guiding Principles.

The non-medical carve-out comes with compliance teeth. Products that market themselves as non-medical BCIs must explicitly state on their labelling and marketing materials that they are not for medical use (不用于医疗目的), and they cannot claim, implicitly or explicitly, that they improve, restore, or replace central nervous system function. This provision has direct commercial implications for consumer wearable EEG headsets, gaming-oriented brain-computer interfaces, and cognitive-augmentation devices operating in the Chinese market. The Meta Neural Band and other surface-electromyography wrist wearables would fall outside the BCI category entirely on the “peripheral signals” exclusion, but any device that reads scalp EEG for wellness or cognitive augmentation now sits under the non-medical labelling requirements.

What the announcement does not resolve

Five specific items are not addressed in the Guiding Principles or in the accompanying interpretive commentary that is publicly accessible. First, whether the announcement has a separate effective date distinct from the 29 June 2026 issuance date. Second, whether previously registered BCI devices, including the Neuracle NEO system that received the NMPA’s first invasive BCI approval in March 2026, are grandfathered under the new classification or must be re-classified. Third, the specific procedural changes to the Class II versus Class III registration pathway that follow from the new classification. Fourth, the enforcement penalties that apply to non-medical BCI products found to breach the labelling requirements. Fifth, any cross-reference to the 23 July 2025 seven-ministry Implementation Opinions on the BCI industry or to the May 2026 Order 818 clinical-translation pathway. The Guiding Principles cite only the underlying Medical Device Supervision and Administration Regulation (《医疗器械监督管理条例》), the Medical Device Classification Catalogue (《医疗器械分类目录》), the Medical Device Classification Rules (Order 15 of 2015), and the AI Medical Device Registration Review Guideline.

The consultation history

The final Guiding Principles follow a draft that was issued for public consultation on 19 March 2026 by the Medical Device Standards Management Center of the National Institute for Food and Drug Control (NIFDC), the NMPA’s technical standards body. The public comment deadline was 17 April 2026. The published comment count is not accessible in the public interpretive documents. The final Guiding Principles text differs from the March draft in at least one substantive way: the draft used the phrase 采用脑机接口技术的医疗器械 (medical devices that employ BCI technology) as its scope description, while the final version narrows this to 脑机接口医疗器械 (BCI medical devices) as a defined category. The narrowing is meaningful because it converts the guidance from a general framework applicable to any device that happens to use BCI components into a specific classification framework for devices that meet the BCI-medical-device definition itself.

The NMPA’s interpretive commentary explicitly caveats the Guiding Principles as being “based on current technological development and cognitive level” (基于目前技术发展现状和当前认知水平下制定的) with a commitment to iterate. Any framing of the announcement as a permanent or final classification framework would misread the NMPA’s own positioning.

Where this sits in the Chinese BCI regulatory frame

The NMPA’s Announcement No. 24 (2026) is the classification-and-scope piece that connects several earlier Chinese BCI regulatory moves into a coherent commercial pathway. The 23 July 2025 seven-ministry Implementation Opinions on Promoting the Innovative Development of the BCI Industry, which Inside BCI covered on 21 June 2026 as part of the three-plans-eight-weeks piece, set the industrial-policy targets. The provincial industrial plans that followed (Shanghai on 10 January 2025, Jiangsu on 10 March 2026, and Guangdong on 24 June 2026) set the geographic clusters and specific yuan-denominated targets. The May 2026 Order 818, which Inside BCI covered on 8 May 2026, established a parallel commercial pathway for clinically translated technologies where hospitals can charge for translated therapies. The March 2026 NMPA approval of the Neuracle NEO system and the April 2026 China guided pricing for invasive BCI procedures set the reimbursement precedent. Announcement No. 24 now locks the classification tier that determines the registration effort, the clinical evidence threshold, and the timeline that any BCI company entering the Chinese market must plan against.

Inside BCI’s ongoing coverage identifies four global BCI regulatory postures: the state-patchwork United States (Colorado, California, Montana, Connecticut enacted), the horizontal-regulator European Union (AI Act plus GDPR plus MDR), the rights-first Chile (constitutional neurorights), and the industrial-builder China with South Korea. Announcement No. 24 fits the industrial-builder posture: rather than restricting BCI development or requiring novel consent frameworks, the NMPA has set a definitive classification structure that lets industry plan, invest, and clinically develop against a known regulatory tier. The narrow Class II lane for stroke-rehab devices without AI is the one exception, and it likely corresponds to a specific commercial signal: China’s rehabilitation-device market is substantially developed at Class II tier, and the NMPA has preserved a on-ramp for BCI devices that fit that existing regulatory infrastructure without requiring full Class III commitment.

What to watch

The first signal is whether the specialist Western regulatory trade (RAPS Regulatory Focus, Emergo by UL, BioWorld MedTech) picks up Announcement No. 24 in the next 3 to 10 days. Absent Western trade coverage at 5 to 6 days post-issuance is notable given the announcement’s commercial significance and may indicate that Western BCI companies have not yet fully absorbed the implications.

The second signal is the treatment of the Neuracle NEO under the new classification. NEO received the NMPA’s first invasive BCI approval in March 2026. Under the new classification, invasive BCIs are unambiguously Class III. Whether Neuracle’s existing approval is grandfathered as Class III or whether the company must re-register under the specific 12-00 subcategory code is a factual question that the Guiding Principles do not answer and that will be tested by Neuracle’s next regulatory disclosure.

The third signal is the practical AI trigger threshold. Non-invasive stroke-rehab devices that use conventional signal processing without machine learning components can enter the Chinese market at Class II. Devices that incorporate any adaptive algorithm may face a re-classification to Class III. The line between “AI” and “not AI” for classification purposes is not sharp, and how the NMPA’s Center for Medical Device Evaluation (CMDE) applies it in specific submissions over the next quarter will determine whether the Class II lane is a genuine commercial on-ramp or a narrow theoretical exception.

The fourth signal is how foreign BCI companies with Chinese ambitions position for the classification. Neuralink, Paradromics, Precision Neuroscience, and Synchron have no publicly disclosed Chinese trial arms as of publication. Whether any of them files an NMPA submission under the new Class III framework in the coming quarters is a commercial signal for the Chinese market’s openness to Western BCI capital and technology.

Sources

• China Clarifies Medical Device Classification for Brain-Computer Interfaces (China Briefing / Dezan Shira & Associates, byline Qian Zhou, 3 July 2026)
• NMPA Announcement No. 24 (2026), Guiding Principles for the Classification and Definition of Brain-Computer Interface Medical Device Products (29 June 2026, primary URL)
• Primary text mirrors: LexisCN metadata + Sina Finance interpretive text + IT之家 verbatim reproduction of NMPA interpretive commentary
• NIFDC draft consultation notice, 19 March 2026 (Medical Device Standards Management Center)
• Inside BCI: Guangdong Dual-Core BCI Action Plan, 26 June 2026 · Order 818 takes effect: BCI joins gene and cell therapy on China’s parallel commercial track, 8 May 2026 · Neuracle STAR Market IPO prospectus accepted, 22 June 2026 · Three BCI industrial policy launches China South Korea eight weeks, 21 June 2026 · Gestala ultrasound BCI Angel+ round, 3 July 2026